Treatment of High-Risk Early Stage Lung Cancer

lt;br /> Jeffrey A. Bogart, M.D., is the current chair of the Department of Radiation Oncology at Upstate Medical University. Bogart, professor of radiation oncology, joined the SUNY Upstate faculty in 1993. He is currently chair or co-chair of eight Cancer and Leukemia Group B (CALGB)-funded multicenter clinical trials and one National Institutes of Health (NIH) study. He serves on several oversight and advisory committees for the NIH. Bogart, a resident of Jamesville, is an active leader in the CALGB for which he currently serves on its Executive Committee, Board of Directors, and as chair of its Radiation Oncology committee. He is also active in a range of other national organizations in therapeutic radiology and oncology. He is a member of the editorial board of The Journal of Clinical Oncology.

The spectrum of tumor aggressiveness in early stage Cancer.- The spectrum of patients with early cancer.- What is the appropriate evaluation for early stage NSCLC.- How do we assess outcomes in high risk patients.- Definition of high risk.- Which tumors are amenable to a lesion-only approach.- Technical consideration of minimally invasive surgery for stage I NSCLC.- Technical considerations of SBRT treatment planning and delivery.- Technical considerations of Ablative treatments (RFA).- Outcomes of surgical resection (VATS lobe, segment, wedge) in high risk patients.- Outcomes of SBRT in high risk patients.- Outcomes of RFA in high risk patients.- How should high-risk patients with peripheral stage I NSCLC be counseled regarding treatment alternatives (SLR vs SBRT vs RFA)?.- Synchronous primary NSCLC lesions / oligometastatic disease.- Considerations of salvage local therapy in previously treated stage I NSCLC.- Which patients with stage I NSCLC may benefit from systemic therapy.- Is there still a role for fractionated radiotherapy in medically inoperable peripheral early stage NSCLC.- Proton and charged particle therapy in the era of SBRT.